Loading…
Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020
As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs). The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immu...
Saved in:
| Published in: | China CDC weekly 2024-12, Vol.6 (50), p.1331-1336 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 1336 |
| container_issue | 50 |
| container_start_page | 1331 |
| container_title | China CDC weekly |
| container_volume | 6 |
| creator | Gao, Linying Cui, Xufeng Mo, Xinyuan Men, Zhaoyue Xu, Xiuyang Yao, Tian Wang, Jianmin Liu, Hongting Guo, Hongping Chai, Guowei Liu, Liming Wang, Fuzhen Liang, Xiaofeng Wang, Suping Feng, Yongliang |
| description | As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).
The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.
The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population. |
| doi_str_mv | 10.46234/ccdcw2024.264 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11673178</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3150136518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1518-9cf07cfeae17589bab1086c49732bb40ab5c9935da92568a22bc2d8a87b1c5033</originalsourceid><addsrcrecordid>eNpVkclOwzAQhi0EolXplSPykUNdvGTzCUEKtKISlViukeM4jVFjlzhp6UPwzliioHKaGc3M988CwDnB4yCiLLiSspBbimkwplFwBPoU8wjFOCbHB34PDJ17xxhTTilNolPQYzxmQZywPvia1XVn7FIZLXW7g7aEz5VtWpTarnFqBKd6WaGJdQpO1Vq0utUO3sI3IaU2PrQGagMX3lOmdXCr2wqmVWM9Dj7qwqgdnGinhO9HnizMp4aLxm60kR6eVh4yghQTjvwa-AyclGLl1HBvB-D1_u4lnaL508MsvZkjSUKSIC5LHMtSCUXiMOG5yAlOIhn4rWieB1jkoeSchYXgNIwSQWkuaZGIJM6JDDFjA3D9w113ea0K6WdvxCpbN7oWzS6zQmf_M0ZX2dJuMkKimBF_uQG43BMa-9Ep12a1dlKtVsIo27mMkRATFvlpfenFodifyu8T2DdpAYpS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3150136518</pqid></control><display><type>article</type><title>Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020</title><source>PubMed Central</source><creator>Gao, Linying ; Cui, Xufeng ; Mo, Xinyuan ; Men, Zhaoyue ; Xu, Xiuyang ; Yao, Tian ; Wang, Jianmin ; Liu, Hongting ; Guo, Hongping ; Chai, Guowei ; Liu, Liming ; Wang, Fuzhen ; Liang, Xiaofeng ; Wang, Suping ; Feng, Yongliang</creator><creatorcontrib>Gao, Linying ; Cui, Xufeng ; Mo, Xinyuan ; Men, Zhaoyue ; Xu, Xiuyang ; Yao, Tian ; Wang, Jianmin ; Liu, Hongting ; Guo, Hongping ; Chai, Guowei ; Liu, Liming ; Wang, Fuzhen ; Liang, Xiaofeng ; Wang, Suping ; Feng, Yongliang</creatorcontrib><description>As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).
The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.
The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.</description><identifier>ISSN: 2096-7071</identifier><identifier>EISSN: 2096-7071</identifier><identifier>DOI: 10.46234/ccdcw2024.264</identifier><identifier>PMID: 39734783</identifier><language>eng</language><publisher>China: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention</publisher><subject>Preplanned Studies</subject><ispartof>China CDC weekly, 2024-12, Vol.6 (50), p.1331-1336</ispartof><rights>Copyright © 2024 by Chinese Center for Disease Control and Prevention.</rights><rights>Copyright © 2024 by Chinese Center for Disease Control and Prevention. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673178/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673178/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39734783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Linying</creatorcontrib><creatorcontrib>Cui, Xufeng</creatorcontrib><creatorcontrib>Mo, Xinyuan</creatorcontrib><creatorcontrib>Men, Zhaoyue</creatorcontrib><creatorcontrib>Xu, Xiuyang</creatorcontrib><creatorcontrib>Yao, Tian</creatorcontrib><creatorcontrib>Wang, Jianmin</creatorcontrib><creatorcontrib>Liu, Hongting</creatorcontrib><creatorcontrib>Guo, Hongping</creatorcontrib><creatorcontrib>Chai, Guowei</creatorcontrib><creatorcontrib>Liu, Liming</creatorcontrib><creatorcontrib>Wang, Fuzhen</creatorcontrib><creatorcontrib>Liang, Xiaofeng</creatorcontrib><creatorcontrib>Wang, Suping</creatorcontrib><creatorcontrib>Feng, Yongliang</creatorcontrib><title>Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020</title><title>China CDC weekly</title><addtitle>China CDC Wkly</addtitle><description>As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).
The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.
The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.</description><subject>Preplanned Studies</subject><issn>2096-7071</issn><issn>2096-7071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkclOwzAQhi0EolXplSPykUNdvGTzCUEKtKISlViukeM4jVFjlzhp6UPwzliioHKaGc3M988CwDnB4yCiLLiSspBbimkwplFwBPoU8wjFOCbHB34PDJ17xxhTTilNolPQYzxmQZywPvia1XVn7FIZLXW7g7aEz5VtWpTarnFqBKd6WaGJdQpO1Vq0utUO3sI3IaU2PrQGagMX3lOmdXCr2wqmVWM9Dj7qwqgdnGinhO9HnizMp4aLxm60kR6eVh4yghQTjvwa-AyclGLl1HBvB-D1_u4lnaL508MsvZkjSUKSIC5LHMtSCUXiMOG5yAlOIhn4rWieB1jkoeSchYXgNIwSQWkuaZGIJM6JDDFjA3D9w113ea0K6WdvxCpbN7oWzS6zQmf_M0ZX2dJuMkKimBF_uQG43BMa-9Ep12a1dlKtVsIo27mMkRATFvlpfenFodifyu8T2DdpAYpS</recordid><startdate>20241213</startdate><enddate>20241213</enddate><creator>Gao, Linying</creator><creator>Cui, Xufeng</creator><creator>Mo, Xinyuan</creator><creator>Men, Zhaoyue</creator><creator>Xu, Xiuyang</creator><creator>Yao, Tian</creator><creator>Wang, Jianmin</creator><creator>Liu, Hongting</creator><creator>Guo, Hongping</creator><creator>Chai, Guowei</creator><creator>Liu, Liming</creator><creator>Wang, Fuzhen</creator><creator>Liang, Xiaofeng</creator><creator>Wang, Suping</creator><creator>Feng, Yongliang</creator><general>Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20241213</creationdate><title>Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020</title><author>Gao, Linying ; Cui, Xufeng ; Mo, Xinyuan ; Men, Zhaoyue ; Xu, Xiuyang ; Yao, Tian ; Wang, Jianmin ; Liu, Hongting ; Guo, Hongping ; Chai, Guowei ; Liu, Liming ; Wang, Fuzhen ; Liang, Xiaofeng ; Wang, Suping ; Feng, Yongliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1518-9cf07cfeae17589bab1086c49732bb40ab5c9935da92568a22bc2d8a87b1c5033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Preplanned Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Linying</creatorcontrib><creatorcontrib>Cui, Xufeng</creatorcontrib><creatorcontrib>Mo, Xinyuan</creatorcontrib><creatorcontrib>Men, Zhaoyue</creatorcontrib><creatorcontrib>Xu, Xiuyang</creatorcontrib><creatorcontrib>Yao, Tian</creatorcontrib><creatorcontrib>Wang, Jianmin</creatorcontrib><creatorcontrib>Liu, Hongting</creatorcontrib><creatorcontrib>Guo, Hongping</creatorcontrib><creatorcontrib>Chai, Guowei</creatorcontrib><creatorcontrib>Liu, Liming</creatorcontrib><creatorcontrib>Wang, Fuzhen</creatorcontrib><creatorcontrib>Liang, Xiaofeng</creatorcontrib><creatorcontrib>Wang, Suping</creatorcontrib><creatorcontrib>Feng, Yongliang</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>China CDC weekly</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Linying</au><au>Cui, Xufeng</au><au>Mo, Xinyuan</au><au>Men, Zhaoyue</au><au>Xu, Xiuyang</au><au>Yao, Tian</au><au>Wang, Jianmin</au><au>Liu, Hongting</au><au>Guo, Hongping</au><au>Chai, Guowei</au><au>Liu, Liming</au><au>Wang, Fuzhen</au><au>Liang, Xiaofeng</au><au>Wang, Suping</au><au>Feng, Yongliang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020</atitle><jtitle>China CDC weekly</jtitle><addtitle>China CDC Wkly</addtitle><date>2024-12-13</date><risdate>2024</risdate><volume>6</volume><issue>50</issue><spage>1331</spage><epage>1336</epage><pages>1331-1336</pages><issn>2096-7071</issn><eissn>2096-7071</eissn><abstract>As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).
The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.
The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.</abstract><cop>China</cop><pub>Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention</pub><pmid>39734783</pmid><doi>10.46234/ccdcw2024.264</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2096-7071 |
| ispartof | China CDC weekly, 2024-12, Vol.6 (50), p.1331-1336 |
| issn | 2096-7071 2096-7071 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11673178 |
| source | PubMed Central |
| subjects | Preplanned Studies |
| title | Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A59%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20Short-Course,%20High-Dose%20Hepatitis%20B%20Vaccination%20in%20Patients%20with%20Chronic%20Kidney%20Disease%20-%20Shanxi%20Province,%20China,%202019-2020&rft.jtitle=China%20CDC%20weekly&rft.au=Gao,%20Linying&rft.date=2024-12-13&rft.volume=6&rft.issue=50&rft.spage=1331&rft.epage=1336&rft.pages=1331-1336&rft.issn=2096-7071&rft.eissn=2096-7071&rft_id=info:doi/10.46234/ccdcw2024.264&rft_dat=%3Cproquest_pubme%3E3150136518%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1518-9cf07cfeae17589bab1086c49732bb40ab5c9935da92568a22bc2d8a87b1c5033%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3150136518&rft_id=info:pmid/39734783&rfr_iscdi=true |